Chisso, Kobe University to Create New Company for Thermoresponsive Magnetic Nanoparticle Therma-Max.
The new company will develop diagnostic agents and testing devices using Therma-Max. A wider range of applications is expected, including genetic and protein analysis, antigen-antibody diagnosis as well as endocrine disruptor testing.
The company will start off with an initial staff of five.
Source: JCN http://www.japancorp.net
Copyright [c] 2005 Japan Corporate News Network. All rights reserved.
|Printer friendly Cite/link Email Feedback|
|Publication:||JCNN News Summaries|
|Date:||Jul 28, 2005|
|Previous Article:||AnGes MG to Start Phase I Clinical Trial of NF-kappa B Decoy Oligodeoxynucleotide for Atopic Dermatitis.|
|Next Article:||Wyeth Japan Obtains Approval for Anti-AML Agent Mylotarg.|